Spandidos Publications Logo
  • About
    • About Spandidos
    • Aims and Scopes
    • Abstracting and Indexing
    • Editorial Policies
    • Reprints and Permissions
    • Job Opportunities
    • Terms and Conditions
    • Contact
  • Journals
    • All Journals
    • Oncology Letters
      • Oncology Letters
      • Information for Authors
      • Editorial Policies
      • Editorial Board
      • Aims and Scope
      • Abstracting and Indexing
      • Bibliographic Information
      • Archive
    • International Journal of Oncology
      • International Journal of Oncology
      • Information for Authors
      • Editorial Policies
      • Editorial Board
      • Aims and Scope
      • Abstracting and Indexing
      • Bibliographic Information
      • Archive
    • Molecular and Clinical Oncology
      • Molecular and Clinical Oncology
      • Information for Authors
      • Editorial Policies
      • Editorial Board
      • Aims and Scope
      • Abstracting and Indexing
      • Bibliographic Information
      • Archive
    • Experimental and Therapeutic Medicine
      • Experimental and Therapeutic Medicine
      • Information for Authors
      • Editorial Policies
      • Editorial Board
      • Aims and Scope
      • Abstracting and Indexing
      • Bibliographic Information
      • Archive
    • International Journal of Molecular Medicine
      • International Journal of Molecular Medicine
      • Information for Authors
      • Editorial Policies
      • Editorial Board
      • Aims and Scope
      • Abstracting and Indexing
      • Bibliographic Information
      • Archive
    • Biomedical Reports
      • Biomedical Reports
      • Information for Authors
      • Editorial Policies
      • Editorial Board
      • Aims and Scope
      • Abstracting and Indexing
      • Bibliographic Information
      • Archive
    • Oncology Reports
      • Oncology Reports
      • Information for Authors
      • Editorial Policies
      • Editorial Board
      • Aims and Scope
      • Abstracting and Indexing
      • Bibliographic Information
      • Archive
    • Molecular Medicine Reports
      • Molecular Medicine Reports
      • Information for Authors
      • Editorial Policies
      • Editorial Board
      • Aims and Scope
      • Abstracting and Indexing
      • Bibliographic Information
      • Archive
    • World Academy of Sciences Journal
      • World Academy of Sciences Journal
      • Information for Authors
      • Editorial Policies
      • Editorial Board
      • Aims and Scope
      • Abstracting and Indexing
      • Bibliographic Information
      • Archive
    • International Journal of Functional Nutrition
      • International Journal of Functional Nutrition
      • Information for Authors
      • Editorial Policies
      • Editorial Board
      • Aims and Scope
      • Abstracting and Indexing
      • Bibliographic Information
      • Archive
    • International Journal of Epigenetics
      • International Journal of Epigenetics
      • Information for Authors
      • Editorial Policies
      • Editorial Board
      • Aims and Scope
      • Abstracting and Indexing
      • Bibliographic Information
      • Archive
    • Medicine International
      • Medicine International
      • Information for Authors
      • Editorial Policies
      • Editorial Board
      • Aims and Scope
      • Abstracting and Indexing
      • Bibliographic Information
      • Archive
  • Articles
  • Information
    • Information for Authors
    • Information for Reviewers
    • Information for Librarians
    • Information for Advertisers
    • Conferences
  • Language Editing
Spandidos Publications Logo
  • About
    • About Spandidos
    • Aims and Scopes
    • Abstracting and Indexing
    • Editorial Policies
    • Reprints and Permissions
    • Job Opportunities
    • Terms and Conditions
    • Contact
  • Journals
    • All Journals
    • Biomedical Reports
      • Information for Authors
      • Editorial Policies
      • Editorial Board
      • Aims and Scope
      • Abstracting and Indexing
      • Bibliographic Information
      • Archive
    • Experimental and Therapeutic Medicine
      • Information for Authors
      • Editorial Policies
      • Editorial Board
      • Aims and Scope
      • Abstracting and Indexing
      • Bibliographic Information
      • Archive
    • International Journal of Epigenetics
      • Information for Authors
      • Editorial Policies
      • Editorial Board
      • Aims and Scope
      • Abstracting and Indexing
      • Bibliographic Information
      • Archive
    • International Journal of Functional Nutrition
      • Information for Authors
      • Editorial Policies
      • Editorial Board
      • Aims and Scope
      • Abstracting and Indexing
      • Bibliographic Information
      • Archive
    • International Journal of Molecular Medicine
      • Information for Authors
      • Editorial Policies
      • Editorial Board
      • Aims and Scope
      • Abstracting and Indexing
      • Bibliographic Information
      • Archive
    • International Journal of Oncology
      • Information for Authors
      • Editorial Policies
      • Editorial Board
      • Aims and Scope
      • Abstracting and Indexing
      • Bibliographic Information
      • Archive
    • Medicine International
      • Information for Authors
      • Editorial Policies
      • Editorial Board
      • Aims and Scope
      • Abstracting and Indexing
      • Bibliographic Information
      • Archive
    • Molecular and Clinical Oncology
      • Information for Authors
      • Editorial Policies
      • Editorial Board
      • Aims and Scope
      • Abstracting and Indexing
      • Bibliographic Information
      • Archive
    • Molecular Medicine Reports
      • Information for Authors
      • Editorial Policies
      • Editorial Board
      • Aims and Scope
      • Abstracting and Indexing
      • Bibliographic Information
      • Archive
    • Oncology Letters
      • Information for Authors
      • Editorial Policies
      • Editorial Board
      • Aims and Scope
      • Abstracting and Indexing
      • Bibliographic Information
      • Archive
    • Oncology Reports
      • Information for Authors
      • Editorial Policies
      • Editorial Board
      • Aims and Scope
      • Abstracting and Indexing
      • Bibliographic Information
      • Archive
    • World Academy of Sciences Journal
      • Information for Authors
      • Editorial Policies
      • Editorial Board
      • Aims and Scope
      • Abstracting and Indexing
      • Bibliographic Information
      • Archive
  • Articles
  • Information
    • For Authors
    • For Reviewers
    • For Librarians
    • For Advertisers
    • Conferences
  • Language Editing
Login Register Submit
  • This site uses cookies
  • You can change your cookie settings at any time by following the instructions in our Cookie Policy. To find out more, you may read our Privacy Policy.

    I agree
Search articles by DOI, keyword, author or affiliation
Search
Advanced Search
presentation
Experimental and Therapeutic Medicine
Join Editorial Board Propose a Special Issue
Print ISSN: 1792-0981 Online ISSN: 1792-1015
Journal Cover
May 2013 Volume 5 Issue 5

Full Size Image

Sign up for eToc alerts
Recommend to Library

Journals

International Journal of Molecular Medicine

International Journal of Molecular Medicine

International Journal of Molecular Medicine is an international journal devoted to molecular mechanisms of human disease.

International Journal of Oncology

International Journal of Oncology

International Journal of Oncology is an international journal devoted to oncology research and cancer treatment.

Molecular Medicine Reports

Molecular Medicine Reports

Covers molecular medicine topics such as pharmacology, pathology, genetics, neuroscience, infectious diseases, molecular cardiology, and molecular surgery.

Oncology Reports

Oncology Reports

Oncology Reports is an international journal devoted to fundamental and applied research in Oncology.

Experimental and Therapeutic Medicine

Experimental and Therapeutic Medicine

Experimental and Therapeutic Medicine is an international journal devoted to laboratory and clinical medicine.

Oncology Letters

Oncology Letters

Oncology Letters is an international journal devoted to Experimental and Clinical Oncology.

Biomedical Reports

Biomedical Reports

Explores a wide range of biological and medical fields, including pharmacology, genetics, microbiology, neuroscience, and molecular cardiology.

Molecular and Clinical Oncology

Molecular and Clinical Oncology

International journal addressing all aspects of oncology research, from tumorigenesis and oncogenes to chemotherapy and metastasis.

World Academy of Sciences Journal

World Academy of Sciences Journal

Multidisciplinary open-access journal spanning biochemistry, genetics, neuroscience, environmental health, and synthetic biology.

International Journal of Functional Nutrition

International Journal of Functional Nutrition

Open-access journal combining biochemistry, pharmacology, immunology, and genetics to advance health through functional nutrition.

International Journal of Epigenetics

International Journal of Epigenetics

Publishes open-access research on using epigenetics to advance understanding and treatment of human disease.

Medicine International

Medicine International

An International Open Access Journal Devoted to General Medicine.

Journal Cover
May 2013 Volume 5 Issue 5

Full Size Image

Sign up for eToc alerts
Recommend to Library

  • Article
  • Citations
    • Cite This Article
    • Download Citation
    • Create Citation Alert
    • Remove Citation Alert
    • Cited By
  • Similar Articles
    • Related Articles (in Spandidos Publications)
    • Similar Articles (Google Scholar)
    • Similar Articles (PubMed)
  • Download PDF
  • Download XML
  • View XML
Article

Analysis and curative effect of ocular ischemic diseases caused by carotid artery stenosis

  • Authors:
    • Yitao Yan
    • Xinli Zhang
    • Yuxin Yang
    • Liying Han
    • Huimin Wang
    • Junxi Hu
  • View Affiliations / Copyright

    Affiliations: Department of Ophthalmology, The First Affiliated Hospital of Xinxiang Medical University, Weihui, Henan 453100, P.R. China, Department of Ophthalmology, The Second People's Hospital of Xinxiang, Xinxiang, Henan 453000, P.R. China, Department of Ophthalmology, Nanyang Eye Hospital, Nanyang, Henan 473014, P.R. China
  • Pages: 1310-1314
    |
    Published online on: February 27, 2013
       https://doi.org/10.3892/etm.2013.979
  • Expand metrics +
Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )
Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )
Cited By (CrossRef): 0 citations Loading Articles...

This article is mentioned in:



Abstract

Carotid artery stenosis is a notable cause of ocular ischemic disease. To analyze the ocular ischemic diseases caused by carotid artery stenosis and to seek effective treatment, a retrospective review of 182 patients with carotid artery stenosis was performed. These patients were administered medical treatment, carotid artery stenting (CAS) or carotid endarterectomy (CEA) and the curative effects of the three different treatments were compared. The results demonstrated that all three treatments helped to improve the disease. Both carotid endarterectomy and carotid artery stenting were more effective than medical treatment (P<0.05). There was no significant difference between carotid endarterectomy and carotid artery stenting (P>0.05). In conclusion, timely diagnosis and suitable treatment for ocular ischemic diseases caused by carotid artery stenosis are necessary due to the complicated clinical manifestation. This study suggested that carotid endarterectomy and carotid artery stenting are effective techniques that may relieve this disease.

Introduction

Carotid artery stenosis is one of the most common neurological diseases. Depending on the severity of this disease, patients show a number of brain and/or ocular ischemic symptoms and signs (1). Considering its high occurrence rate in neurology and its correlation with risk factors such as gender, hypertension and smoking, ocular ischemic diseases caused by carotid artery stenosis are generally recognized as a neurological disease (2,3). Complex and diverse clinical manifestations of the disease may, however, lead to a missed diagnosis or misdiagnosis. Some patients may then develop amaurosis fugax, diplopia, decreased vision or permanent blindness. Doctors must therefore analyze conditions thoroughly to offer timely and effective treatments.

Some scholars (1) specifically defined ‘ocular ischemic syndrome’ as a series of brain and eye clinical syndromes caused by chronic severe carotid artery obstruction or stenosis resulting in brain and eye insufficiency. However, in this study, a generalized concept was applied and all ocular ischemic diseases related with carotid artery obstruction or stenosis were analyzed, including ocular ischemic syndrome (according to definition), retinal central/branch vein occlusion, external ophthalmoplegia, ischemic optic neuropathy and neovascular glaucoma. By retrospective analysis of patients with carotid artery stenosis who were diagnosed at the First Affiliated Hospital of Xinxiang Medical University in recent years, the related etiological factors, clinical presentations and treatment effects were investigated.

Subjects and methods

Subjects

The clinical data were gathered from 182 patients with carotid artery stenosis who were diagnosed in the ophthalmology, neurology, neurosurgery or intervention departments of the First Affiliated Hospital of Xinxiang Medical University (Weihui, China) from January 2002 to November 2009. Among them, 107 were males and 75 were females aged between 24 and 87 years (mean, 65.24±8.65 years). All patients were diagnosed using carotid color Doppler or digital subtraction angiography (DSA) to exclude the possibility of various primary eye diseases, such as primary glaucoma, iridocyclitis, retinal vein occlusion, high myopia, retinal pigment degeneration, retinochoroiditis, diabetic retinopathy or congenital fundus anomaly. This study was conducted in accordance with the declaration of Helsinki, and with the approval of the Ethics Committee of the First Affiliated Hospital of Xinxiang Medical University. Written informed consent was obtained from all participants.

Patients’ general information

The clinical data of the patients were gathered for retrospective analysis. The data included general characteristics of patients, body and eye medical histories (including amaurosis fugax and eye pain), past medical histories (including hypertension, diabetes, hyperlipidemia and coronary heart disease), personal histories (including smoking and drinking), the department where the patient was first treated, detailed eye symptoms and treatment procedures. The 182 patients were divided into two groups; 78 cases with ocular ischemic symptoms were classified as group A and 104 cases without ocular ischemic symptoms were classified as group B.

The 78 cases in group A were treated with drugs (including antihypertensives, antihyperglycemic agents, antihyperlipidemic agents or anticoagulants in a total of 19 cases), carotid artery stenting (26 cases) or carotid endarterectomy (33 cases). Certain patients with ocular ischemic symptoms also received eye treatments concomitantly (such as retinal laser photocoagulation, drugs to lower intraocular pressure or cyclocryotherapy).

Evaluation criteria

The position and degree of the carotid artery stenosis were judged according to the results of the angiography. The status of the ophthalmic artery hemodynamics was analyzed using color Doppler flow imaging (Philips HD7). The detection frequency was 10 MHz and various ophthalmic artery hemodynamic indices were measured, including peak systolic velocity (Psv), end diastolic velocity (Edv), mean glow velocity (Vm), resistive index (RI) and pulsatility index (PI). Each index was measured in triplicate and the mean value was used for further analysis.

The effects of different treatments on group A patients were evaluated according to the following scale: i) Significantly effective; the patient felt that eye condition improved markedly. Vision of patients with decreased visual acuity was improved at least 2 lines after treatment, or ophthalmic artery hemodynamic indices were obviously improved; ii) Improved; the patient felt that eye status remained stable or had mild improvement. Vision of patients with decreased visual acuity was improved 1 line or remained stable after treatment, or ophthalmic artery hemodynamic indices showed some improvement; iii) Invalid; the patient felt symptoms were worse or vision decreased or ophthalmic artery hemodynamic indices were notably decreased; iv) Uncertain; the patient had occasional ocular ischemic symptoms or had no ophthalmic artery hemodynamic indices.

Statistical analysis

Statistical data were presented as means ± SD or a percentage. The data were analyzed using SPSS 14.0 software (SPSS Inc., Chicago, IL, USA) for the t-test and χ2 test to calculate whether the two groups were statistically different. To avoid confounding and interaction between disease-related factors, one-way ANOVA and unconditional logistic regression were performed to analyze the correlation between various factors and onsets of the two groups of patients. P<0.05 was considered to indicate a statistically significant result.

Results

Comparison of patient age and gender

Among 182 patients, 19 were aged <50, 35 were aged 51 to 60, 68 were aged 61 to 70, 45 were aged 71 to 80, and 15 were aged >80. The average age of group A (64.41±9.45) was a little higher than that of group B (62.12±11.32) but there was no significant statistical difference (t=0.754, P>0.05).

The position and degree of carotid artery stenosis

Carotid artery stenosis of both group A and B patients was mainly located in the common carotid artery bifurcation and internal carotid artery inlet. In group A, 75.64% (59) of cases had an over half diameter reduction and the degree of stenosis was 43–100% (mean, 69.13±7.46). The degree of stenosis in group B was 34–100% (mean, 48.34±9.23). There was a significant difference between the degree of the two groups (t=0.754, P>0.05).

Risk factors associated with carotid artery stenosis

Group A consisted of 43 males and 35 females, including 46 patients with hypertension, 41 with hyperlipidemia and 35 smokers; group B consisted of 59 males and 45 females, including 53 patients with hypertension, 48 with hyperlipidemia and 40 smokers. According to the results of one-way ANOVA and unconditional logistic regression, the onset of carotid artery stenosis was closely associated with gender (male), hypertension, hyperlipidemia and smoking (χ2=4.562, 5.151, 4.471 and 4.463, respectively; P<0.05).

Distribution of first-visit patients

Among the 78 patients with ocular ischemic symptoms (group A), 39 were first seen in the Neurology department (20 of them transferred to interventional treatment later) and 31 were first seen in Neurosurgery (4 of them transferred to interventional treatment later). Only 8 patients were first seen in Ophthalmology (2 of them transferred to Neurosurgery and 2 patients transferred to interventional treatment later).

Incidence of ocular ischemic diseases

In addition to investigating ophthalmic medical records (including retinal hemorrhage, edema, visual field defects and increased intraocular pressure), discharged patients were followed up. Patients of group A recalled several symptoms, such as amaurosis fugax, eye swelling and periorbital pains (ischemia of ocular anterior segment) or diplopia. The frequencies of ocular ischemic symptoms are shown in Table I.

Table I

The ocular ischemic symptoms and their frequency in group A.

Table I

The ocular ischemic symptoms and their frequency in group A.

Symptoms and signsNo. of casesPercentage of cases
Amaurosis fugax3747.44
Eye and periorbital pains2835.90
Diplopia1114.10
Hypopsia (visual field defects)2633.33
Retinal hemorrhage, edema1924.36
Increased intraocular pressure33.85

[i] Among 78 cases, certain patients had two or more symptoms.

Composition of ocular ischemic diseases

After classifying cases according to final diagnoses, 31 patients in group A had ocular ischemic diseases. The composition is shown in Table II.

Table II

Composition of ocular ischemic diseases in group A (n=31).

Table II

Composition of ocular ischemic diseases in group A (n=31).

DiseasesNo. of casesConstituent ratio (%)
Ischemic optic neuropathy1032.26
Ocular ischemia syndrome722.58
Retinal central/branch vein occlusion722.58
External ophthalmoplegia412.90
Neovascular glaucoma39.68
Ophthalmology treatments

In the 8 patients who were first seen in Ophthalmology, 3 patients with ischemic optic neuropathy (Fig. 1) and 3 patients with retinal vein occlusion had been given several treatments, such as drugs to lower intraocular pressure, hypodermic injection with anisodine on the temporal side or circulation-improving medications. Two patients with neovascular glaucoma had been treated with retinal laser photocoagulation and cyclocryotherapy, respectively. The other 56 patients of group A had no eye symptoms (such as amaurosis fugax) or only had transient symptoms (such as eye swelling, periorbital pains, diplopia) so they were not diagnosed or misdiagnosed and not administered specific treatment.

Figure 1

Group of images revealed ischemic optic neuropathy caused by carotid artery stenosis (female, 57 years old). (A) Fundus photograph of the right eye with ischemic optic neuropathy. (B) Fundus photograph of the left eye with ischemic optic neuropathy showed features of fundus lesions. (C) Carotid artery color Doppler ultrasound showed severe stenosis of the carotid artery and thrombogenesis in the patient. (D) Transcranial Doppler sonography showed increased resistance in the carotid siphon (indicating carotid artery stenosis). (E) FFA of the left eye showed fuzzy boundaries of the optic disc, surface telangiectasia, narrowed arteries and venous dilation. (F) FFA of the right eye showed fuzzy boundaries of optic disc, surface telangiectasia, narrowed arteries and venous dilation. FFA, fundus fluorescein angiography.

Ophthalmic artery hemodynamics indices

In the 78 patients of group A, the ophthalmic artery hemodynamics index of 34 patients was examined with color Doppler flow imaging-before and 3 months after treatment. The results suggested that all indices were significantly improved (P<0.01) after treatment with carotid artery stenting (13 cases) and carotid endarterectomy (11 cases). The indices were also improved after medical treatment (10 cases) but the difference was not statistically significant (P>0.05) (Tables III, IV and V).

Table III

Comparison of ophthalmic artery hemodynamic indices before and after medical treatment (mean ± SD, n=10).

Table III

Comparison of ophthalmic artery hemodynamic indices before and after medical treatment (mean ± SD, n=10).

IndexBefore treatmentAfter treatmentD-valueP-value
Psv (cm/sec)18.74±5.1727.54±6.878.80±5.580.067
Edv (cm/sec)13.31±4.2318.36±5.215.05±4.940.053
Vm (cm/sec)14.57±5.0320.17±6.075.60±6.160.057
RI0.8±0.140.43±0.110.41±0.210.058
PI1.48±0.470.81±0.290.67±0.380.063

[i] Psv, peak systolic velocity; Edv, end diastolic velocity; Vm, mean glow velocity; RI, resistive index; PI, pulsatility index.

Table IV

Comparison of ophthalmic artery hemodynamic indices before and after surgical treatment (mean ± SD, n=11).

Table IV

Comparison of ophthalmic artery hemodynamic indices before and after surgical treatment (mean ± SD, n=11).

IndexBefore treatmentAfter treatmentD-valueP-value
Psv (cm/sec)9.12±2.2828.58±3.6319.46±4.01<0.01
Edv (cm/sec)7.03±1.3520.83±3.1213.80±2.42<0.01
Vm (cm/sec)8.09±1.8525.83±3.5617.74±3.31<0.01
RI1.17±0.060.33±0.090.84±0.03<0.01
PI1.69±0.290.61±0.131.08±0.32<0.01

[i] Psv, peak systolic velocity; Edv, end diastolic velocity; Vm, mean glow velocity; RI, resistive index; PI, pulsatility index.

Table V

Comparison of ophthalmic artery hemodynamic indices before and after interventional treatment (mean ± SD, n=13).

Table V

Comparison of ophthalmic artery hemodynamic indices before and after interventional treatment (mean ± SD, n=13).

IndexBefore treatmentAfter treatmentD-valueP-value
Psv (cm/sec)8.32±2.2824.91±3.7616.59±3.91<0.01
Edv (cm/sec)7.17±1.3520.72±2.9213.55±2.24<0.01
Vm (cm/sec)8.76±1.8525.30±3.7316.56±2.93<0.01
RI1.28±0.060.52±0.140.76±0.11<0.01
PI1.58±0.290.61±0.230.97±0.36<0.01

[i] Psv, peak systolic velocity; Edv, end diastolic velocity; Vm, mean glow velocity; RI, resistive index; PI, pulsatility index.

Treatment effects

Following the comprehensive analyses of patient information, the results of treatment effects are summarized in Table VI. The total effective rates of surgical and interventional treatment were higher than those observed with medical treatment (t=2.725, t=3.137, P<0.01).

Table VI

Comparison of effects of three different treatment methods.

Table VI

Comparison of effects of three different treatment methods.

TreatmentSignificantly effectiveImprovedInvalidUncertainTotal effective rate(%)
Medical358342.11
Interventional1293280.77
Surgical17113284.85

Discussion

Ocular ischemic diseases are a series of symptoms and signs, such as ocular anterior or posterior segment ischemia, that result from insufficient blood supply from the ophthalmic artery for a number of reasons (including carotid stenosis or occlusion). Ocular ischemic diseases include the following five categories: i) Ocular ischemic (hypoperfusion) syndrome. Carotid arterial atherosclerosis is the main cause, and Raynaud’s disease (also known as acral artery spasm caused by vasospastic disorder) is another possible cause. ii) Obstruction of the central retinal artery. iii) Retinal vein occlusion (ischemic type). The lumen is narrowed while the vein passes through the sieve plate area. iv) Ischemic optic neuropathy. v) Carotid cavernous fistula. Ocular ischemic diseases in the acute phase show amaurosis fugax, retinal central/branch vein occlusion, eye swelling or periorbital pains (ischemia of ocular anterior segment). As the disease develops, ocular ischemic syndrome and hypoperfusion retinopathy ultimately develop into neovascular glaucoma in the chronic phase, leading to permanent blindness (4–6).

This analysis of general information revealed that patients with ocular ischemic diseases caused by carotid artery stenosis were mostly elderly (mean age, 64.37±9.70). One-way ANOVA and unconditional logistic regression analyses also suggested that the onset of carotid artery stenosis was closely related with gender (male), hypertension, hyperlipidemia and smoking. These conclusions agreed with a previous epidemiological survey (7).

Angiography analysis showed that 75.64% (59 cases) of patients with ocular ischemic symptoms in group A had an over half diameter reduction following treatment. The degree of stenosis (mean, 69.13±7.46) was significantly higher than group B (mean, 48.34±9.23). This difference implied that ocular ischemic symptoms were one of the important signs of severe carotid artery stenosis. The majority of the 78 patients in group A were first seen in the Neurology or Neurosurgery departments. Only 8 cases (10.26%) were first diagnosed in Ophthalmology. Another 14 cases (17.95%) were seen in Ophthalmology following consultations in Neurology or Neurosurgery. The other 56 patients (71.79%) were not diagnosed or misdiagnosed, as eye symptoms (such as amaurosis fugax) were absent or only had transient symptoms (such as eye swelling, periorbital pains or diplopia). Some patients developed neovascular glaucoma and permanent blindness due to lack of timely treatment. Conversely, chief complaints including amaurosis fugax, conjunctival swelling, periorbital pains and diplopia were often misdiagnosed as asthenopia, conjunctivitis, supraorbital neuralgia and ophthalmoplegia by ophthalmologists, leading to delayed treatments.

The analyses of ocular ischemic disease composition suggested that in patients with carotid artery stenosis associated with ocular ischemic symptoms, ischemic optic neuropathy (32.26%) ranked first, followed by ocular ischemia syndrome (22.58%) and retinal central/branch vein occlusion (22.58%). External ophthalmoplegia (12.90%) and neovascular glaucoma (9.68%) ranked fourth and fifth respectively. The data provided advantageous indications for investigating risk factors of ophthalmic clinical diseases. If unexplained clinical situations, such as decreased vision, retinal central/branch vein occlusion, ocular ischemic diseases, external ophthalmoplegia or neovascular glaucoma occur, doctors should be alert to the possibility of carotid artery stenosis.

The three main treatment methods for carotid artery stenosis are medical, surgical (carotid endarterectomy) and interventional (carotid artery stenting) treatments. Therapists often provide treatments according to the degree of stenosis, age and the overall condition. Havelius et al(8) reported that scotopic vision and photosensitivity of patients improved significantly after carotid endarterectomy. Wolintz et al(9) suggested that surgical treatments were helpful for improving blood flow to the brain and eye but not for eyesight.

Most researchers (10) considered that clinical applications of carotid endarterectomy and carotid artery stenting had been used in many cases over many years, and its stable effects had been confirmed. In addition, patients treated with carotid endarterectomy or carotid artery stenting are usually provided adjuvant medical treatment, such as aspirin for anticoagulation. This comprehensive surgical treatment improves ophthalmic artery hemodynamics more effectively after carotid endarterectomy and carotid artery stenting compared with absolute medical treatment. However, there have been no large-scale clinical experiments to judge the curative effects of carotid endarterectomy or interventional treatment for eyesight improvement in China or abroad as yet (11).

This study further indicated that total effective rates of surgical and interventional treatment were higher than absolute medical treatment. Consequently, besides the necessary ophthalmic treatments, surgical and interventional treatments should also be actively applied to patients with ocular ischemic symptoms caused by carotid artery stenosis. This will help treat the primary disease and promote eye blood circulation in a timely and effective manner. In addition, the curative effects of nearly 1/5 patients were found to be invalid or uncertain after surgical or interventional treatments. This is because vision is often improved in patients with mild to moderate ocular ischemic disease but not in diseases of long duration, neovascularization disease or secondary fundus hemorrhage. Fundus lesions and visual impairment of patients with severe ocular ischemic syndromes may be irreversible, even if the ocular blood supply and flow are improved effectively. Diagnosis and treatment in a timely and correct manner is the best way to treat declining eyesight caused by carotid artery stenosis.

References

1. 

Wang YL, Zhao L, Huang YX, Feng X and Li MM: Clinical characteristics of ocular ischemic syndromes. Zhonghua Yan Ke Za Zhi. 45:1080–1083. 2009.(In Chinese).

2. 

Zheng Y, Hua Y, Ling C, et al: Correlation analysis between risk factors of carotid artery stenosis and ischemic stroke. Chin J Ultrasound Diagnosis. 5:4–6. 2004.

3. 

Zhao HQ, Pan XD, Wang JH, et al: Common causes of carotid artery stenosis. Foreign Med Sci (Section of Cranial vascular disease). 12:4972004.

4. 

Zhang HR: Ocular changes caused by carotid artery obstruction or stenosis. Eye Encyclopedia (middle volume). Li FM: People’s Medical Publishing House; Beijing: pp. 2306–2308. 1995

5. 

Takaki Y, Nagata M, Shinoda K, et al: Severe acute ocular ischemia associated with spontaneous internal carotid artery dissection. Int Ophthalmol. 28:447–449. 2008. View Article : Google Scholar : PubMed/NCBI

6. 

Telman G, Kouperberg E, Nitecki S, et al: Cerebral hemodynamics in symptomatic and asymptomatic patients with severe unilateral carotid stenosis before and after carotid endarterectomy. Eur J Vasc Endovasc Surg. 32:375–378. 2006. View Article : Google Scholar : PubMed/NCBI

7. 

Chen CS and Miller NR: Ocular ischemic syndrome: review of clinical presentations, etiology, investigation, and management. Compr Ophthalmol Update. 8:17–28. 2007.PubMed/NCBI

8. 

Havelius U, Bergqvist D, Hindfelt B and Krakau T: Improved dark adaptation after carotid endarterectomy. Evidence of a long-term Ischemic penumbra Neurology. 49:1360–1364. 1997.PubMed/NCBI

9. 

Wolintz RJ: Carotid endarterectomy for ophthalmic manifestations: is it ever indicated? J Neuroophthalmol. 25:299–302. 2005. View Article : Google Scholar : PubMed/NCBI

10. 

Faries PL, Chaer RA, Patel S, Lin SC, DeRubertis B and Kent KC: Current management of extracranial carotid artery disease. Vasc Endovascular Surg. 40:165–175. 2006. View Article : Google Scholar : PubMed/NCBI

11. 

Malhotra R and Gregory-Evans K: Management of ocular ischemic syndrome. Br J Ophthalmol. 84:1428–1431. 2000. View Article : Google Scholar

Related Articles

  • Abstract
  • View
  • Download
  • Twitter
Copy and paste a formatted citation
Spandidos Publications style
Yan Y, Zhang X, Yang Y, Han L, Wang H and Hu J: Analysis and curative effect of ocular ischemic diseases caused by carotid artery stenosis. Exp Ther Med 5: 1310-1314, 2013.
APA
Yan, Y., Zhang, X., Yang, Y., Han, L., Wang, H., & Hu, J. (2013). Analysis and curative effect of ocular ischemic diseases caused by carotid artery stenosis. Experimental and Therapeutic Medicine, 5, 1310-1314. https://doi.org/10.3892/etm.2013.979
MLA
Yan, Y., Zhang, X., Yang, Y., Han, L., Wang, H., Hu, J."Analysis and curative effect of ocular ischemic diseases caused by carotid artery stenosis". Experimental and Therapeutic Medicine 5.5 (2013): 1310-1314.
Chicago
Yan, Y., Zhang, X., Yang, Y., Han, L., Wang, H., Hu, J."Analysis and curative effect of ocular ischemic diseases caused by carotid artery stenosis". Experimental and Therapeutic Medicine 5, no. 5 (2013): 1310-1314. https://doi.org/10.3892/etm.2013.979
Copy and paste a formatted citation
x
Spandidos Publications style
Yan Y, Zhang X, Yang Y, Han L, Wang H and Hu J: Analysis and curative effect of ocular ischemic diseases caused by carotid artery stenosis. Exp Ther Med 5: 1310-1314, 2013.
APA
Yan, Y., Zhang, X., Yang, Y., Han, L., Wang, H., & Hu, J. (2013). Analysis and curative effect of ocular ischemic diseases caused by carotid artery stenosis. Experimental and Therapeutic Medicine, 5, 1310-1314. https://doi.org/10.3892/etm.2013.979
MLA
Yan, Y., Zhang, X., Yang, Y., Han, L., Wang, H., Hu, J."Analysis and curative effect of ocular ischemic diseases caused by carotid artery stenosis". Experimental and Therapeutic Medicine 5.5 (2013): 1310-1314.
Chicago
Yan, Y., Zhang, X., Yang, Y., Han, L., Wang, H., Hu, J."Analysis and curative effect of ocular ischemic diseases caused by carotid artery stenosis". Experimental and Therapeutic Medicine 5, no. 5 (2013): 1310-1314. https://doi.org/10.3892/etm.2013.979
Follow us
  • Twitter
  • LinkedIn
  • Facebook
About
  • Spandidos Publications
  • Careers
  • Cookie Policy
  • Privacy Policy
How can we help?
  • Help
  • Live Chat
  • Contact
  • Email to our Support Team